· Event impact
Big Pharma Enters 'Merger Mania' as $300B Patent Cliff Looms
Type: corporateConfidence: 0.85Verified: keep
Transmission path
Strategic acquisitions to replace lost revenue from expiring patents.
Market mechanism
Strategic acquisitions to replace lost revenue from expiring patents.
Extended read
The pharmaceutical sector is undergoing a massive consolidation phase as major players face the expiration of key patents. With $300 billion in revenue at risk, companies like Eli Lilly, Merck, and Pfizer are pursuing bolt-on acquisitions to bolster their pipelines. This 'merger mania' is also providing a significant boost to investment banking revenues, which have rebounded sharply in the first half of 2026.
Exposed assets
GS · LLY
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →